SNX16 is required for hepatocellular carcinoma survival via modulating the EGFR-AKT signaling pathway

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Sorting nexin 16 (SNX16) is implicated in tumor progression, but its specific role in hepatocellular carcinoma (HCC) is not well understood.
• Understanding SNX16's molecular mechanisms in HCC is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the function and clinical significance of SNX16 in hepatocellular carcinoma (HCC).
• To elucidate the molecular pathways regulated by SNX16 in HCC, including the EGFR-AKT signaling cascade.

Main Methods:

• Analysis of SNX16 mRNA and protein expression in HCC tissues.
• In vitro assays involving SNX16 overexpression and knockdown in HCC cell lines to assess effects on proliferation, invasion, and epithelial-mesenchymal transition (EMT).
• Investigation of SNX16's impact on the EGFR-AKT signaling pathway.

Main Results:

• SNX16 overexpression in HCC correlates with poorer patient survival and promotes HCC cell proliferation, migration, invasion, and tumorigenicity.
• SNX16 knockdown inhibits these aggressive phenotypes in HCC cells.
• SNX16 downregulates phospho-EGFR, thereby suppressing AKT signaling, and EGFR inhibition reverses SNX16-induced HCC progression.

Conclusions:

• SNX16 plays a significant role in promoting hepatocellular carcinoma (HCC) progression through the EGFR-AKT signaling pathway.
• SNX16 represents a potential therapeutic target for the treatment of HCC.